Biodegradable nanocarriers coated with polymyxin B: Evaluation of leishmanicidal and antibacterial potential

Autor(es)

Ribeiro Costa, Juliana Souza ^{[1, 2]} ; Medeiros, Marilia ^[1] ; Yamashiro-Kanashiro, Edite Harumi ^[3] ; Rocha, Mussya Cisotto ^[3] ; Cotrim, Paulo Cesar ^[3] ; Stephano, Marco Antonio ^[4] ; Lancellotti, Marcelo ^{[1, 2]} ; Tavares, Guilherme Diniz ^[5] ; Oliveira-Nascimento, Laura ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Fac Pharmaceut Sci, Campinas, SP - Brazil

^[2] Univ Estadual Campinas, Biol Inst, Dept Biochem & Tissue Biol, Campinas, SP - Brazil

^[3] Univ Sao Paulo, Trop Med Inst, Sao Paulo, SP - Brazil

^[4] Univ Sao Paulo, Sch Pharmaceut Sci, Sao Paulo, SP - Brazil

^[5] Univ Estadual Campinas, Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: PLoS Neglected Tropical Diseases; v. 13, n. 5 MAY 2019.
• Citações Web of Science: 0

Resumo

Most treatments of leishmaniasis require hospitalization and present side effects or parasite resistance; innovations in drug formulation/reposition can overcome these barriers and must be pursued to increase therapeutic alternatives. Therefore, we tested polymyxin B (polB) potential to kill Leishmania amazonensis, adsorbed or not in PBCA nanoparticles (PBCAnp), which could augment polB internalization in infected macrophages. PBCAnps were fabricated by anionic polymerization and analyzed by Dynamic Light Scattering (size, potential), Nanoparticle Tracking Analysis (size/concentration), vertical diffusion cell (release rate), drug incorporation (indirect method, protein determination) and in vitro cell viability. Nanoparticles coated with polB (PBCAnp-polB) presented an adequate size of 261.5 25.9 nm, low PDI and of 1.79 +/- 0.17 mV (stable for 45 days, at least). The 50% drug release from PBCAnp-polB was 6-7 times slower than the free polB, which favors a prolonged and desired release profile. Concerning in vitro evaluations, polB alone reduced in vitro amastigote infection of macrophages (10 g/mL) without complete parasite elimination, even at higher concentrations. This behavior limits its future application to adjuvant leishmanicidal therapy or antimicrobial coating of carriers. The nanocarrier PBCAnp also presented leishmanicidal effect and surpassed polB activity; however, no antimicrobial activity was detected. PolB maintained its activity against E. coli, Pseudomonas and Klebsiella, adding antimicrobial properties to the nanoparticles. Thus, this coated drug delivery system, described for the first time, demonstrated antileishmanial and antimicrobial properties. The bactericidal feature helps with concomitant prevention/treatment of secondary infections that worst ulcers induced by cutaneous L. amazonensis, ultimately ending in disfiguring or disabling lesions. Author summary Cutaneous leishmaniasis form disfiguring lesions that leads to depression and social isolation. Both consequences result often in economic and education loss for communities already short on resources. The actual treatment aims to eliminate the protozoa disease-vector. Yet, it presents undesired effects or parasite resistance, besides the need for intravenous infusions and hospitalization. There is a few topical leishmanicidals but none with prolonged action. As highlighted, no ideal therapy exists; we must keep searching for alternatives, which includes new drugs, vehicles or therapies. For drugs, the most cost-effective way comprises testing approved molecules for other diseases, such as the antimicrobial polymyxin B (polB). Repositioning a drug has the added benefit of known safety profile and drawbacks, shortening and narrowing the research path. In turn, carriers can decrease side-effects and multiple dosing. They shield and/or improve drug targeting, which in this case means delivering inside macrophages infected with Leishmania. An example is poly (n-butyl cyanoacrylate) nanoparticles (PBCAnp), shown as an efficient carrier for targeting an extended drug release. Therefore, this work aimed to evaluate leishmanicidal and adjuvant properties of polB, alone and absorbed onto PBCAnp. (AU)

• Processo FAPESP: 13/16588-7 - Nanoestruturas biopoliméricas para veiculação de peptídeos antimicrobianos com potencial leishmanicida
• Beneficiário: Laura de Oliveira Nascimento
• Modalidade de apoio: Auxílio à Pesquisa - Regular